viewPreveCeutical Medical Inc.

Preveceutical Medical making headway with cannabinoid delivery system

Health sciences and in particular new ways of thinking about drug delivery and disease prevention have made some significant advances in recent times.

One company on the cutting edge of preventative medicine is Vancouver based PreveCeutical Medical (CSE: PREV) (OTC: PRVCF) which focuses on innovation in the health science space.

The company's research team, led by Harry Parekh out of the R&D laboratory at the University of Queensland, has some exciting developments in drug delivery and pain management.

Preveceutical Medical is currently working on applying its Sol Gel technology to the delivery of cannabinoids to effectively treat  diseases like multiple sclerosis, paediatric epilepsy and chronic pain.

Maher Khaled, the CEO of the company's Australian arm, says the business is also looking for new opportunities as scientific evidence for cannabinoid treatments builds.

"We'll be looking at other areas and diseases where strong evidence comes to support them as we progress" says Mr Khaled.

Quick facts: PreveCeutical Medical Inc.

Price: 0.08 CAD

Market: CSE
Market Cap: $31.72 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...



PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 27/4/19

2 min read